Ras GTPase-activating protein 2 (RASA2) (RASA2)

Ras GTPase-activating protein 2 (RASA2) is a member of the GAP1 family of GTPase-activating proteins that serves as a critical negative regulator of the Ras signaling pathway (UniProt Q15283). By stimulating the intrinsic GTPase activity of Ras proteins, RASA2 promotes the conversion of active Ras-GTP to inactive Ras-GDP, thereby dampening downstream MAPK/ERK signaling (PubMed: 7759471). In the context of immunology, RASA2 has been identified as a key signaling "brake" in human T cells; its genetic ablation via CRISPR/Cas9 has been shown to enhance T cell effector function, persistence, and resistance to exhaustion in CAR-T cell therapies (Carnevale et al., Nature 2022). Beyond its role in immune modulation, RASA2 acts as a tumor suppressor in various malignancies, such as melanoma, where loss-of-function mutations lead to sustained Ras activation and uncontrolled cell proliferation (PubMed: 26173930). Additionally, germline mutations in RASA2 are linked to Noonan syndrome-like conditions, highlighting its importance in developmental signaling regulation (PubMed: 26173930). As a therapeutic target, RASA2 is primarily being explored through gene-editing strategies to improve the efficacy of adoptive cellular immunotherapies against solid tumors.

Other names

GAP1MRasGAP-activating protein 2p120GAP-related proteinGAP1(m)

Genetic ablation or knockout of the RASA2 gene is employed to remove a negative regulator of Ras signaling, thereby enhancing the potency, persistence, and anti-tumor activity of engineered T cells (e.g., CAR-T cells) by preventing exhaustion (Carnevale et al., Nature 2022).